4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:癌症、免疫、炎症、代谢疾病(糖尿病、肥胖)、干细胞和神经退行性疾病等领域
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > Other_reagents > Adipogen/Orlistat/AG-CN2-0050-M050/50 mg
商品详细Adipogen/Orlistat/AG-CN2-0050-M050/50 mg
Adipogen/Orlistat/AG-CN2-0050-M050/50 mg
Adipogen/Orlistat/AG-CN2-0050-M050/50 mg
商品编号: AG-CN2-0050-M050
品牌: Adipogen Inc
市场价: ¥600.00
美元价: 360.00
产地: 美国(厂家直采)
公司:
产品分类: 其他试剂
公司分类: Other_reagents
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
More Information
Product Details
Synonyms Tetrahydrolipstatin; Xenical; Alli; Ro-18-0647
Product Type Chemical
Properties
Formula C29H53NO5
MW 495.7
Merck Index 14: 6869
CAS 96829-58-2
Source/Host Chemicals Synthetic. Originally isolated from Streptomyces sp.
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white solid.
Solubility Soluble in DMSO, ethanol or DMF.
Identity Determined by HPLC and IR.
InChi Key AHLBNYSZXLDEJQ-FWEHEUNISA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After reconstitution, prepare aliquots and store at -20°C.
Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Hypolipemic cell permeable and irreversible pancreatic, gastric and carboxylester lipase inhibitor [1-3].
  • Anti-obesity and antihypercholesterolemic compound [2, 5, 11].
  • Antitumor compound by inhibition of the thioesterase domain of fatty acid synthase (FASN) [4, 6, 9, 10].
  • Anti-proliferative [4, 6, 9, 10].
  • Causes cell cycle arrest at G1 phase. Apoptosis inducer through caspase-3 activation [6, 10].
  • Sn-1-selective-diacylglycerol lipases α (DAGLα) inhibitor. Targets serine hydrolases in the nervous system, such as diacylglycerol lipase (DAGL), which is responsible for the conversion of DAG to 2-AG [7].
  • Partially inhibits the hydrolysis of triglycerides and lowers the absorption of dietary fat, promoting weight loss [8].
  • Promotes the sensitivity to TRAIL in cancer cells by ROS-mediated pathways [11].
Product References
  1. Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat): A. Lookene, et al.; Eur. J. Biochem. 222, 395 (1994)
  2. Mode of action of orlistat: R. Guerciolini; Int. J Obes. Relat. Metab. Disord. 2, S12 (1997) (Review)
  3. Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine: B. Sternby, et al.; Clin. Nutr. 21, 395 (2002)
  4. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity: S.J. Kridel, et al.; Cancer Res. 64, 2070 (2004)
  5. The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes: R.H. Nelson & J.M. Miles; Expert Opin. Pharmacother. 6, 2483 (2005) (Review)
  6. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene: J.A. Menendez, et al.; Ann. Oncol. 16, 1253 (2005)
  7. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis: T. Bisogno, et al.; Biochim. Biophys. Acta 1761, 205 (2006)
  8. Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects: F.Y. Enc, et al.; Am. J. Physiol. Gastrointest. Liver Physiol. 296, G482 (2008)
  9. Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model: M.A. Carvalho, et al.; Int. J. Cancer. 123, 2557 (2008)
  10. Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal: H.Y. Chuang, et al.; Biomed. Pharmacother. 65, 286 (2011)
  11. The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells: J. Fujiwara, et al.; Int. J. Oncol. 48, 854 (2016)
品牌介绍
Adipogen公司由三个子公司组成,分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国,运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发,如癌症、免疫、炎症、代谢疾病(糖尿病、肥胖)、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外,也可提供抗体和蛋白产品,Adipogen拥有自己的化学实验室,致力于开发创新型小分子化合物。